Revenio Group Corporation, Stock Exchange Release, May 15, 2015 at 14:00
PAYING REVENIO GROUP CORPORATION BOARD MEMBERS' FEES IN THE FORM OF SHARES HELD BY THE COMPANY
With reference to Board meeting fees, Revenio Group Corporation's AGM decided on 19th of March 2015 that 40% of the fee paid to a board member should be paid in company shares. According to the decisions taken at the AGM and by the Board, Revenio Group Corporation has transferred to Board members a total of 2,147 shares as a part of their Board fees as follows:
A total of 715 shares were transferred to chairman of the Board Pekka Tammela. As a result of the transfer, his holdings in Revenio Group Corporation and other instruments issued by Revenio Group Corporation amount to 31,069 shares.
A total of 358 shares were transferred to Board member Rolf Fryckman. As a result of the transfer, his holdings in Revenio Group Corporation and other instruments issued by Revenio Group Corporation amount to 13,698 shares.
A total of 358 shares were transferred to Board member Ari Kohonen. As a result of the transfer, his and his nearparty holdings in Revenio Group Corporation and other instruments amount to 341,860 shares.
A total of 358 shares were transferred to Board member Pekka Rönkä. As a result of the transfer, his holdings in Revenio Group Corporation and other instruments issued by Revenio Group Corporation amount to 801 shares.
A total of 358 shares were transferred to Board member Kyösti Kakkonen. As a result of the transfer, his and his nearparty holdings in Revenio Group Corporation and other instruments issued by Revenio Group Corporation amount to 442,310 shares.
As a result of these transfers, the share-based Board member fees have been completely settled for the year 2015. Revenio Group Corporation now holds a total of 554 of its own shares.
Revenio Group Corporation
Olli-Pekka Salovaara
President and CEO
The Revenio Group in brief
Revenio is a Finnish health tech group whose core business is in tonometers. TheRevenio Health Tech segment comprises the business operations of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis screening and monitoring. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology lies on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki.